Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fennec Pharmaceuticals reports Q1 loss, sees growth in new therapies

Fennec Pharmaceuticals' Q1 2023 earnings call highlighted a mix of financial results, market strategies, and analyst inquiries. Despite challenges in achieving profitability, the company showcased strengths in product launches and market acceptance. Opportunities for growth through expanded adoption, market strategies, and R&D investments were discussed.

Fennec Pharmaceuticals reports robust revenue growth and strategic milestones in Q2 2023

Fennec Pharmaceuticals demonstrated strong revenue growth and key regulatory milestones in Q2 2023, positioning the company for future success.
While facing financial challenges and operational inquiries, Fennec's strategic focus on commercial expansion and patient support programs remains a key strength.
With a solid cash position and experienced leadership, Fennec is well-positioned to capitalize on market opportunities and drive further growth in the oncology sector.

Fennec Pharmaceuticals excels in Q3 with PEDMARK growth strategies

Fennec Pharmaceuticals demonstrated robust financial performance and strategic market positioning in Q3 2023, leveraging the successful launch of PEDMARK in the U.S. and plans for European expansion.
While facing challenges in metrics tracking, manufacturing transitions, and pipeline prioritization, the company remains focused on maximizing PEDMARK's market potential and competitive edge.
Opportunities lie in expanding market presence in Europe, negotiating favorable pricing strategies, and solidifying PEDMARK's position as a key therapy alongside cisplatin.

Fennec Pharmaceuticals excels in Q4 2023, secures strategic partnerships

Fennec Pharmaceuticals delivered strong financial results and strategic advancements in Q4 2023, positioning the company for growth.
While facing challenges in increased expenses and access barriers, Fennec's focus on pediatric oncology and strategic partnerships offer promising opportunities.
With a solid financial foundation and market endorsements, Fennec is well-positioned to capitalize on its growth potential and expand its market presence.

Fennec Pharmaceuticals reports solid Q1 performance amidst market challenges

Fennec Pharmaceuticals navigated challenges in Q1 2024 while maintaining strong financial performance and strategic advancements. The company's focus on resolving issues, expanding market reach, and optimizing sales strategies positions it for future success.

Fennec Pharmaceuticals reports solid Q2 performance, eyes market expansion

Fennec Pharmaceuticals' Q2 2024 performance reflects progress in PEDMARK's commercialization and market access.
While facing challenges in specific business segments, the company's strong financial position and strategic partnerships are notable strengths.
Opportunities lie in targeted market expansion and clear communication of growth strategies to investors.

Fennec Pharmaceuticals reports robust Q3 performance and eyes international expansion

Fennec Pharmaceuticals showcased solid financial performance in Q3 2024, with a strong focus on the AYA market.
The company's strategic imperatives for PEDMARK and leadership enhancements position it for future growth.
While challenges exist in increasing awareness and managing expenses, opportunities in revenue growth and market expansion are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call.

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.07 per share a year ago.

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call.

Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago.

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m.

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr.

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

dLocal Ltd

Direct Digital Holdings

Investing in dirt cheap stocks under $10 has a lot of appeal. One of the benefits is that a low share price allows you to buy more shares with a smaller amount of money.

3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.

Fennec Pharmaceuticals Announces Management Change

RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Financial Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Chase Knickerbocker - Craig Hallum Michael Okunewitch - Maxim Group Raghuram Selvaraju - HC Wainwright Operator Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' First Quarter 2024 Earnings and Corporate Update Conference Call.

Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.23 per share a year ago.

Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates

~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago.

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates

~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.

News for Fennec Pharmaceuticals Stock (FENC)